Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688685 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Evaluate CAD-1883 in Essential Tremor
A Phase 2 study, sponsored by Cadent Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03688685 is a Phase 2 study that has completed, run by Cadent Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT03688685, a Phase 2 study, has completed, sponsored by Cadent Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented severity of tremor based on the clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.
Interventions
- DRUG CAD-1883
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688685
The ClinicalTrials.gov registry entry for NCT03688685 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cadent Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAD-1883 is the first listed.
NCT03688685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03688685 about?
NCT03688685 is a clinical study titled "A Clinical Study to Evaluate CAD-1883 in Essential Tremor". This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria wi...
What is the current status of trial NCT03688685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2019-01-23. Estimated completion is 2019-09-24.
What interventions are being tested in trial NCT03688685?
The interventions under investigation include: CAD-1883 (DRUG).
Who is sponsoring clinical trial NCT03688685?
This trial is sponsored by Cadent Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.